Literature DB >> 17261705

Use of a poly(ADP-ribose) polymerase inhibitor to suppress inflammation and neuronal death after cerebral ischemia-reperfusion.

Aaron M Hamby1, Sang Won Suh, Tiina M Kauppinen, Raymond A Swanson.   

Abstract

BACKGROUND AND
PURPOSE: Most stroke patients do not present for medical treatment until several hours after onset of brain ischemia. Consequently, neuroprotective strategies are required with comparably long therapeutic windows. Poly(ADP-ribose) polymerase inhibitors such as PJ34 are known to suppress microglial activation, a postischemic event that may contribute to neuronal death. We evaluated the effects of PJ34 administered 8 hours after transient forebrain ischemia.
METHODS: Rats were subjected to 10 minutes of forebrain ischemia and treated with PJ34 for 7 days beginning 8 hours after reperfusion. Activated microglia and infiltrating macrophages were evaluated at serial time points between zero and 14 days after ischemia by immunostaining for CD11b. CA1 neuronal survival was evaluated 7 days after ischemia.
RESULTS: Rats treated with PJ34 showed a near-complete inhibition of microglia/macrophage activation (evaluated on day 5) and an 84% reduction in CA1 neuronal death.
CONCLUSIONS: Administration of PJ34 as late as 8 hours after transient ischemia-reperfusion has a large protective effect on CA1 survival. This effect may be mediated by suppression of the postischemic brain inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17261705     DOI: 10.1161/01.STR.0000250742.61241.79

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  49 in total

Review 1.  Microglial activation in stroke: therapeutic targets.

Authors:  Midori A Yenari; Tiina M Kauppinen; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

Review 2.  Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities.

Authors:  Amos A Fatokun; Valina L Dawson; Ted M Dawson
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 3.  Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies.

Authors:  David J Loane; Alan I Faden
Journal:  Trends Pharmacol Sci       Date:  2010-10-29       Impact factor: 14.819

4.  Deletion of Nuclear Factor kappa B p50 Subunit Decreases Inflammatory Response and Mildly Protects Neurons from Transient Forebrain Ischemia-induced Damage.

Authors:  Taisia Rolova; Hiramani Dhungana; Paula Korhonen; Piia Valonen; Natalia Kolosowska; Henna Konttinen; Katja Kanninen; Heikki Tanila; Tarja Malm; Jari Koistinaho
Journal:  Aging Dis       Date:  2015-11-23       Impact factor: 6.745

5.  Neuronal protective role of PBEF in a mouse model of cerebral ischemia.

Authors:  Weiping Zhang; Yicheng Xie; Tiannan Wang; Jing Bi; Hailong Li; Li Qin Zhang; Shui Qing Ye; Shinghua Ding
Journal:  J Cereb Blood Flow Metab       Date:  2010-05-19       Impact factor: 6.200

6.  Poly(ADP-ribose) polymerase-1 and its cleavage products differentially modulate cellular protection through NF-kappaB-dependent signaling.

Authors:  Paola Castri; Yang-Ja Lee; Todd Ponzio; Dragan Maric; Maria Spatz; Joliet Bembry; John Hallenbeck
Journal:  Biochim Biophys Acta       Date:  2014-03

Review 7.  Sex differences in stroke therapies.

Authors:  Farida Sohrabji; Min Jung Park; Amanda H Mahnke
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

8.  Neuroprotective effects of ethyl pyruvate on brain energy metabolism after ischemia-reperfusion injury: a 31P-nuclear magnetic resonance study.

Authors:  Osamu Tokumaru; Chihiro Kuroki; Noriko Yoshimura; Tetsuro Sakamoto; Hidehiro Takei; Kazue Ogata; Takaaki Kitano; Naoko Nisimaru; Isao Yokoi
Journal:  Neurochem Res       Date:  2008-11-05       Impact factor: 3.996

9.  Diffuse axonal damage, myelin impairment, astrocytosis and inflammatory response following microinjections of NMDA into the rat striatum.

Authors:  Rafael R Lima; Joanilson Guimaraes-Silva; Jorge L Oliveira; Ana Maria R Costa; Renata D Souza-Rodrigues; Claudia D Dos Santos; Cristovam W Picanço-Diniz; Walace Gomes-Leal
Journal:  Inflammation       Date:  2007-09-25       Impact factor: 4.092

Review 10.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.